351 related articles for article (PubMed ID: 8970247)
21. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
Boyle JE; Ghosh K; Gieser DK; Adamsons IA
Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
[TBL] [Abstract][Full Text] [Related]
22. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
23. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.
Adkins JC; Balfour JA
Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study.
Shedden A; Laurence J; Tipping R;
Clin Ther; 2001 Mar; 23(3):440-50. PubMed ID: 11318078
[TBL] [Abstract][Full Text] [Related]
25. Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension.
Netland PA; Michael M; Rosner SA; Katzman B; Macy JI
Adv Ther; 2003; 20(1):20-30. PubMed ID: 12772815
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II.
Javitt J; Goldberg I
J Glaucoma; 2000 Oct; 9(5):398-408. PubMed ID: 11039742
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
Simmons ST;
Clin Ther; 2001 Apr; 23(4):604-19. PubMed ID: 11354394
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Whitson JT; Henry C; Hughes B; Lee DA; Terry S; Fechtner RD
J Glaucoma; 2004 Apr; 13(2):168-73. PubMed ID: 15097265
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
[TBL] [Abstract][Full Text] [Related]
30. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide.
Hommer A; Kapik B; Shams N;
Br J Ophthalmol; 2003 May; 87(5):592-8. PubMed ID: 12714402
[TBL] [Abstract][Full Text] [Related]
31. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
32. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure.
Stewart WC; Sharpe ED; Harbin TS; Pastor SA; Day DG; Holmes KT; Stewart JA
Am J Ophthalmol; 2000 Jun; 129(6):723-7. PubMed ID: 10926979
[TBL] [Abstract][Full Text] [Related]
33. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
Simmons ST; Earl ML;
Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
[TBL] [Abstract][Full Text] [Related]
34. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.
Walters TR
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S19-26. PubMed ID: 8970246
[TBL] [Abstract][Full Text] [Related]
35. Brimonidine tartrate: a one-month dose response study.
Derick RJ; Robin AL; Walters TR; Barnebey HS; Choplin N; Schuman J; Kelley EP; Chen K; Stoecker JF
Ophthalmology; 1997 Jan; 104(1):131-6. PubMed ID: 9022117
[TBL] [Abstract][Full Text] [Related]
36. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
Goñi FJ;
Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
[TBL] [Abstract][Full Text] [Related]
37. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group.
Stewart WC; Laibovitz R; Horwitz B; Stewart RH; Ritch R; Kottler M
Arch Ophthalmol; 1996 Aug; 114(8):938-42. PubMed ID: 8694728
[TBL] [Abstract][Full Text] [Related]
38. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
[TBL] [Abstract][Full Text] [Related]
39. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.
Frampton JE
Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399
[TBL] [Abstract][Full Text] [Related]
40. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data.
Nordmann JP; Mertz B; Yannoulis NC; Schwenninger C; Kapik B; Shams N;
Am J Ophthalmol; 2002 Jan; 133(1):1-10. PubMed ID: 11755834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]